Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
PLoS One. 2013 Aug 19;8(8):e71843. doi: 10.1371/journal.pone.0071843. eCollection 2013.
To investigate colonic mucus thickness in vivo in health and during experimental inflammatory bowel disease.
Colitis was induced with 5% DSS in drinking water for 8 days prior to experiment, when the descending colonic mucosa of anesthetized rats was studied using intravital microscopy. Mucus thickness was measured with micropipettes attached to a micromanipulator. To assess the contributions of NOS and prostaglandins in the regulation of colonic mucus thickness, the non-selective NOS-inhibitor L-NNA (10 mg/kg bolus followed by 3 mg/kg/h), the selective iNOS-inhibitor L-NIL (10 mg/kg bolus followed by 3 mg/kg/h) and the non-selective COX-inhibitor diclofenac (5 mg/kg) were administered intravenously prior to experiment. To further investigate the role of iNOS in the regulation of colonic mucus thickness, iNOS -/- mice were used.
Colitic rats had a thicker firmly adherent mucus layer following 8 days of DSS treatment than untreated rats (88±2 µm vs 76±1 µm). During induction of colitis, the thickness of the colonic mucus layer initially decreased but was from day 3 significantly thicker than in untreated rats. Diclofenac reduced the mucus thickness similarly in colitic and untreated rats (-16±5 µm vs -14±2 µm). While L-NNA had no effect on colonic mucus thickness in DSS or untreated controls (+3±2 µm vs +3±1 µm), L-NIL reduced the mucus thickness significantly more in colitic rats than in controls (-33±4 µm vs -10±3 µm). The importance of iNOS in regulating the colonic mucus thickness was confirmed in iNOS-/- mice, which had thinner colonic mucus than wild-type mice (35±3 µm vs 50±2 µm, respectively). Furthermore, immunohistochemistry revealed increased levels of iNOS in the colonic surface epithelium following DSS treatment.
Both prostaglandins and nitric oxide regulate basal colonic mucus thickness. During onset of colitis, the thickness of the mucus layer is initially reduced followed by an iNOS mediated increase.
研究健康状态下和实验性炎症性肠病(IBD)期间体内结肠黏液层的厚度。
实验前,用 5% DSS 饮用水诱导大鼠结肠炎 8 天,然后在麻醉大鼠下行活体显微镜下研究降结肠黏膜。用连接在微操纵器上的微吸管测量黏液厚度。为了评估 NOS 和前列腺素在调节结肠黏液厚度中的作用,在实验前静脉给予非选择性 NOS 抑制剂 L-NNA(10mg/kg 推注,然后 3mg/kg/h)、选择性 iNOS 抑制剂 L-NIL(10mg/kg 推注,然后 3mg/kg/h)和非选择性 COX 抑制剂双氯芬酸(5mg/kg)。为了进一步研究 iNOS 在调节结肠黏液厚度中的作用,使用了 iNOS-/- 小鼠。
与未处理的大鼠相比,经过 8 天 DSS 处理的结肠炎大鼠的结肠黏液层更厚且更牢固地附着(88±2µm 比 76±1µm)。在结肠炎诱导期间,结肠黏液层的厚度最初减少,但从第 3 天开始明显比未处理的大鼠厚。双氯芬酸在结肠炎和未处理的大鼠中同样减少了黏液厚度(-16±5µm 比-14±2µm)。虽然 L-NNA 对 DSS 或未处理的对照大鼠的结肠黏液厚度没有影响(+3±2µm 比+3±1µm),但 L-NIL 在结肠炎大鼠中的作用比对照组更显著地减少了黏液厚度(-33±4µm 比-10±3µm)。在 iNOS-/- 小鼠中证实了 iNOS 在调节结肠黏液厚度中的重要性,iNOS-/- 小鼠的结肠黏液比野生型小鼠薄(35±3µm 比 50±2µm)。此外,免疫组织化学显示 DSS 处理后结肠表面上皮中 iNOS 水平升高。
前列腺素和一氧化氮都调节基础结肠黏液厚度。在结肠炎发作期间,黏液层的厚度最初减少,随后是 iNOS 介导的增加。